Clinical Updates Exhibit 99.1 Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update RENEW Phase 2 trial evaluating the safety, tolerability, and ef icacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026 Two abstracts accepted to the American Thoracic Society (ATS) 2025 International Conference Cash runway extended following previously announced warrant transactions and private placement AUSTIN, Texas ...